

Association Between *CNDP1* Genotype and Diabetic Nephropathy Is Sex Specific

Antien L. Mooyaart,¹ Ana Zutinic,¹ Stephan J.L. Bakker,² Diana C. Grootendorst,³ Nanne Kleefstra,^{4,5} Irene G.M. van Valkengoed,⁶ Stefan Böhringer,⁷ Henk J.G. Bilo,^{4,8} Friedo W. Dekker,³ Jan Anthonie Bruijn,¹ Gerjan Navis,² Bart Janssen,^{9,10} Hans J. Baelde,¹ and Emile De Heer¹

OBJECTIVE—The 5-5 homozygous *CNDP1* (carnosinase) genotype is associated with a reduced risk of diabetic nephropathy. We investigated whether this association is sex specific and independent of susceptibility for type 2 diabetes.

RESEARCH DESIGN AND METHODS—Three separate groups of 114, 90, and 66 patients with type 2 diabetes and diabetic nephropathy were included in this study and compared with 93 patients with type 2 diabetes for >15 years without diabetic nephropathy and 472 population control subjects. The diabetes control group was used to determine an association in the three patient groups separately, and the population control group was used to estimate the genotype risk [odds ratio (OR)] for the population in a pooled analysis. The population control subjects were also compared with 562 patients with type 2 diabetes without diabetic nephropathy to determine whether the association was independent of type 2 diabetes. The *CNDP1* genotype was determined by fragment analysis after PCR amplification.

RESULTS—The frequency of the 5-5 homozygous genotype was 28, 36, and 41% in the three diabetic nephropathy patient groups and 43 and 42% in the diabetic and population control subjects, respectively. The 5-5 homozygous genotype occurred significantly less frequently in women in all three patient groups compared with diabetic control subjects. The genotype risk for the population was estimated to be 0.5 (0.30–0.68) in women and 1.2 (0.77–1.69) in men. The 562 patients with type 2 diabetes without diabetic nephropathy did not differ from the general population ($P = 0.23$).

CONCLUSIONS—This study suggests that the association between the *CNDP1* gene and diabetic nephropathy is sex specific and independent of susceptibility for type 2 diabetes. *Diabetes* 59:1555–1559, 2010

From ¹Pathology, Leiden University Medical Center, Leiden, the Netherlands; ²Nephrology, University Medical Center Groningen, Groningen, the Netherlands; ³Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; the ⁴Diabetes Centre, Isala Clinic, Zwolle, the Netherlands; the ⁵Medical Research Group, Langerhans, Zwolle, the Netherlands; ⁶Social Medicine, Academic Medical Center, Amsterdam, the Netherlands; the ⁷Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, the Netherlands; ⁸Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands; the ⁹Institute of Human Genetics, Heidelberg, Germany; and ¹⁰ServiceXS, Leiden, the Netherlands.

Corresponding author: Antien L. Mooyaart, a.l.mooyaart@lumc.nl.
Received 16 September 2009 and accepted 8 March 2010. Published ahead of print at <http://diabetes.diabetesjournals.org> on 23 March 2010. DOI: 10.2337/db09-1377.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Only 20–40% of patients with type 1 or type 2 diabetes will develop diabetic nephropathy, and if no signs of nephropathy are present in the first 15 years after diagnosis of diabetes, the chance of ever developing nephropathy is small (1). Furthermore, sibling studies show a strong familial component for development of diabetic nephropathy (2,3), and certain ethnic groups seem to be at a greater risk of developing nephropathy (2,4). These findings suggest that there is a genetic susceptibility component for diabetic nephropathy.

Many genes are thought to be involved in diabetic nephropathy (rev. in 5). One of the genes associated with nephropathy in both patients with type 1 and type 2 diabetes is the *CNDP1* gene, which encodes serum carnosinase (6). This was confirmed in European Americans with end-stage diabetic nephropathy due to type 2 diabetes (7), but the association between diabetic nephropathy and the *CNDP1* gene could not be confirmed in patients with diabetic nephropathy due to type 1 diabetes (8,9) nor in African Americans (7).

Patients with type 2 diabetes of Caucasian origin with homozygosity for five leucine repeats in exon 2 demonstrated a reduced susceptibility for developing diabetic nephropathy compared with individuals with six to eight repeats (6,7,10). With increasing numbers of leucine repeats, the secretion of serum carnosinase has been shown to increase (11) and to lead to higher serum carnosinase activity (4,6). Serum carnosinase degrades carnosines and other histidine-containing dipeptides. Carnosines and related dipeptides are known for their reactive oxygen scavenging effects (12), for degrading advanced glycation end products (13), and for reducing the transforming growth factor (TGF)- β -induced synthesis of extracellular matrix components (6).

Some genes involved in diabetic nephropathy have been shown to have sex specific effects (14,15). For example, the RANTES receptor gene (*CCR5*) is only associated with diabetic nephropathy in men (14), and two single nucleotide polymorphisms in the podocyte slit diaphragm gene (*ACTN4*) were only associated with diabetic nephropathy in women (15).

Therefore, we investigated whether the association between the *CNDP1* gene and diabetic nephropathy due to type 2 diabetes is sex specific. Furthermore, we studied whether the association between diabetic nephropathy and the *CNDP1* gene is independent of the susceptibility for type 2 diabetes itself.

TABLE 1
Baseline characteristics

	Diabetic nephropathy groups			Type 2 diabetes >15 years without diabetic nephropathy
	1	2	3	
Total (<i>n</i>)	114	90	66	93
Age (years)	64.0 ± 11.07	73.4 ± 8.40 ^{†‡}	66.2 ± 8.97	65.8 ± 11.30
Sex (<i>n</i> (%) male)	64 (56.1)	30 (33.3) ^{†‡}	35 (53.0)	47 (50.5)
Diabetes duration (years)	14.3 ± 8.38 [†]	9.7 ± 9.51 ^{†‡}	15.2 ± 10.99 [†]	22.2 ± 6.78
A1C (%)	7.5 ± 1.71	7.5 ± 1.2	—	7.3 ± 1.51
Women				
Age (years)	64.2 ± 11.64	72.2 ± 9.09 ^{†‡}	67.2 ± 7.57	65.1 ± 12.07
Diabetes duration (years)	14.8 ± 9.24 [†]	9.2 ± 7.77 ^{†‡}	15.9 ± 11.83 [†]	22.9 ± 6.50
A1C (%)	8.0 ± 2.08	7.4 ± 1.12	—	7.5 ± 1.65
Men				
Age (years)	63.7 ± 10.68	75.9 ± 6.22 ^{†‡}	65.3 ± 10.07	66.4 ± 10.60
Diabetes duration (years)	13.9 ± 7.81 [†]	10.7 ± 12.4 [†]	14.7 ± 10.39 [†]	21.6 ± 7.05
A1C (%)	7.2 ± 1.32	7.6 ± 1.38	—	7.6 ± 1.38

[†] $P < 0.05$ compared with type 2 diabetes >15 years without diabetic nephropathy. [‡] $P < 0.05$ compared with either diabetic nephropathy group 1 or 3. No significant differences were seen between group 1 and 3 or between women and men in each of the groups.

RESEARCH DESIGN AND METHODS

The institutional medical ethics committees of the participating hospitals approved of the studies described below.

Case groups. For the first case group, female and male Caucasian diabetic patients with diabetic nephropathy from the case-control study of Janssen et al. (6) were reassessed separately. Diabetic nephropathy was defined as diabetes with retinopathy with either macroalbuminuria or as being on dialysis (because of diabetic nephropathy). The details of the recruitment of this cohort are described elsewhere (6). In the present analysis, only 114 diabetic nephropathy patients with type 2 diabetes were included, and this group will be referred to as diabetic nephropathy group 1.

For the second case group, diabetic nephropathy patients were selected from the ZODIAC (Zwolle Outpatient Diabetes Project Integrating Available Care) study (16). Diabetic nephropathy was defined as having either an estimated glomerular filtration rate <60 ml/min/1.73 m² (17) in combination with an albumin excretion >30 mg/l (18) or macroalbuminuria (>300 mg/l) in combination with retinopathy (19). ZODIAC was a cross-sectional single-center study investigating only patients with type 2 diabetes, selected from a population of $>95\%$ Caucasian origin. Patients were recruited from 61 general practitioners from 1998 to 2000. In this study, 90 diabetic nephropathy patients were identified, and these will be referred to as diabetic nephropathy group 2.

For the third group, diabetic nephropathy patients were selected out of a total of 875 patients from the NECOSAD (Netherlands Cooperative Study on the Adequacy of Dialysis) study (20). NECOSAD is a multicenter prospective follow-up study of patients with end-stage renal disease who were included at the start of dialysis, between 1997 and 2005. For the present analysis, only patients with type 2 diabetes of Caucasian origin and end-stage renal disease due to diabetic nephropathy were selected; 66 diabetic nephropathy patients were included and are referred to as diabetic nephropathy group 3.

Control groups. The first control group is a diabetic group, consisting of Caucasian patients with type 2 diabetes without microalbuminuria for at least 15 years, in the absence of ACE inhibitor treatment (6,16). This control group is referred to as diabetic non-nephropathy control subjects.

The second control group is a population control group selected from the SUNSET (Surinamese in the Netherlands: Study on health and Ethnicity) study, a population-based cross-sectional survey (21). In brief, between 2001 and 2003, a random sample of noninstitutionalized adults aged 35–60 years was selected. In the present study, only the 472 white Dutch participants, of whom the genotypic distribution was described in a previous report (4), are used and referred to as population control subjects.

To investigate whether the association between diabetic nephropathy and the *CNDP1* gene is not due to susceptibility for type 2 diabetes, we additionally studied 562 patients with type 2 diabetes without diabetic nephropathy (defined as any of the criteria above) selected from the ZODIAC study participants, referred to as the type 2 diabetes population, to compare with the general population.

Genotyping. Genotyping was performed as described previously (4). In brief, after PCR amplification, fragment analysis was performed on the ABI-3130 analyzer to determine the number of leucine repeats in each allele. The success rate was on average 95%, and no errors were detected. Genotyping

was performed partially in Leiden and in Mannheim. Some of the samples were measured in both institutes, and there was a 100% concordance.

Statistical analysis. The baseline characteristics of the groups are presented as means and SDs or percentages. Continuous variables were tested using the Student *t* test and numeric variables using χ^2 . All groups were tested for Hardy-Weinberg equilibrium, using a χ^2 test.

First, the frequency of the 5-5 homozygous genotype in the respective diabetic nephropathy groups was compared with the 93 diabetic non-nephropathy control subjects stratified by sex, to investigate the relevance of the genotype to disease etiology.

Second, the genotype risk for the population was estimated through comparison of the diabetic nephropathy groups with population control subjects. Odds ratios with CIs were calculated. A pooled analysis was performed to determine the total effect for females and males separately, combining the three case groups when compared with sex-matched population control subjects. The fixed-effects model (inverse variance method) was used when heterogeneity was $P > 0.1$ (χ^2) and the random-effects model when heterogeneity was $P < 0.1$.

Finally, to assess whether the susceptibility for diabetic nephropathy is independent of susceptibility for type 2 diabetes, we compared the type 2 diabetes population with population control subjects.

The statistical analyses were all performed using SPSS 16.0 and R version 2.9.0.

RESULTS

The baseline characteristics of the three diabetic nephropathy groups are described in Table 1, and comparisons are made with diabetic non-nephropathy control subjects. Baseline characteristics did not differ between diabetic non-nephropathy control subjects and the type 2 diabetes population, except for diabetes duration (data not shown). There was no significant difference in 5-5 homozygous genotype frequency between the diabetic non-nephropathy control subjects and the population control subjects consisting of all patients ($P = 0.8$), all women ($P = 0.07$), or all men ($P = 0.13$). All cohorts were in the Hardy-Weinberg equilibrium (found in the online appendix, available at <http://diabetes.diabetesjournals.org/cgi/content/full/db09-1377/DC1>).

Relevance of the 5-5 homozygous genotype to disease etiology. Overall, the 5-5 homozygous genotype frequency of the diabetic nephropathy groups did not differ from the diabetic non-nephropathy control subjects or between the diabetic nephropathy groups ($P = 0.2$). Women in all three diabetic nephropathy groups had a significantly lower frequency of the 5-5 homozygous genotype than female

TABLE 2
The relation between 5-5 homozygous genotype and diabetic nephropathy

	Diabetic nephropathy groups			Type 2 diabetes >15 years without diabetic nephropathy
	1	2	3	
Total				
<i>n</i>	114	90	66	93
Frequency 5-5 (%)	28.1	35.6	40.9	43.0
<i>P</i> *	0.03	0.30	0.80	
Women				
<i>n</i>	50	60	31	46
Frequency 5-5 (%)	24.0	28.3	25.8	58.7
<i>P</i> *	0.001	0.002	0.006	
Men				
<i>n</i>	64	30	35	47
Frequency 5-5 (%)	31.2	50.0	53.4	27.7
<i>P</i> *	0.62	0.05	0.02	

*Compared with type 2 diabetes >15 years without diabetic nephropathy.

diabetic non-nephropathy control subjects (Table 2), also after Bonferroni adjustment for multiple testing. In contrast, men in all three diabetic nephropathy groups had a higher frequency of the 5-5 homozygous genotype than male diabetic non-nephropathy control subjects.

Genotype risk for the population. No heterogeneity was detected in women ($P = 0.64$), but heterogeneity was detected in men ($P = 0.09$). The three diabetic nephropathy groups were pooled for women and men separately, resulting in a genotype risk of 0.5 (0.30–0.68) in women and 1.2 (0.77–1.69) in men (Fig. 1).

Specificity of 5-5 homozygous genotype for diabetic nephropathy, not type 2 diabetes. The 5-5 homozygous genotype frequency of both the 562 type 2 diabetic individuals and the 472 population control subjects are shown in Table 3, showing similar frequency of the 5-5 homozygous genotype.

DISCUSSION

Our results show a sex specific effect of the *CNDP1* genotype in relation to diabetic nephropathy, suggesting that the 5-5 homozygous genotype is only protective in women. The frequency of the 5-5 homozygous genotype was determined in three independent diabetic nephropathy groups. These groups were compared with two control groups: patients with type 2 diabetes and a low risk of ever developing diabetic nephropathy and a sample from the general population. Compared with the diabetic control group, the 5-5 homozygous genotype frequency was significantly lower in women with diabetic nephropathy in all three cohorts, but not in men. The population control group serves to estimate the genotype risk for the population, showing that women with the 5-5 homozygous genotype have a twofold reduced risk of ever developing diabetic nephropathy. Furthermore, this study shows similar frequencies of the 5-5 homozygous genotype in a large type 2 diabetes population and the general population, underlining that the association with diabetic nephropathy is independent of a genetic susceptibility for type 2 diabetes.

The 5-5 homozygous genotype leads to lower carnosinase activity compared with the other genotypes (4,6),




FIG. 1. The relationship between the 5-5 homozygous *CNDP1* genotype and diabetic nephropathy (DN) in women (A) and men (B) in the three independent diabetic nephropathy groups and a pooled analysis (total) compared with population control subjects. The filled diamonds represent the odds ratios of the independent diabetic nephropathy groups and the filled square represents the pooled odds ratio.

leaving more carnosine free to protect the kidney from oxidative stress. Since men have higher carnosine levels in their muscle tissue and women have slightly higher serum carnosinase levels (22), differences in carnosinase activity due to the different *CNDP1* polymorphism may have a stronger impact in women. Carnosine content in the muscles of female mice was shown to increase after testosterone administration, and the increase was 268%

TABLE 3
Comparison between type 2 diabetes population and population control subjects

	Type 2 diabetes population	Population control subjects	<i>P</i>
Total (<i>n</i>)	562	472	
Frequency 5-5 (%)	38.1	41.7	0.23
Women (<i>n</i>)	319	239	
Frequency 5-5 (%)	39.5	43.9	0.23
Men (<i>n</i>)	243	233	
Frequency 5-5 (%)	36.7	39.5	0.58

(23). This might be because carnosine synthetase, the enzyme that synthesizes carnosine, is upregulated by testosterone. It is possible that this phenomenon plays a role in diabetic nephropathy, because both carnosine synthetase (preliminary results) and androgen receptors are expressed in human kidney (24).

Another explanation for the sex specific effect found in this study is that the association between the *CNDP1* gene and diabetic nephropathy is lost in men due to selective survival by cardiovascular disease. As carnosine has shown to be protective against oxidative stress and hemodynamic damage (6,12,13), this might also explain its role in cardiovascular death in diabetic nephropathy patients. Men with diabetic nephropathy due to type 2 diabetes have a higher risk for cardiovascular disease than women (25). Therefore, this might be more prominent in men. Further support for this theory comes from the ZODIAC study. Men with a diabetes duration <10 years and the 5-5 homozygous genotype have a significantly lower mortality risk due to cardiovascular disease than patients with >10 leucine repeats in the *CNDP1* genotype (data not shown). We found no difference in cardiovascular death between the different genotypes in women. These findings need to be replicated in an independent study.

The relatively older age of diabetic nephropathy group 2 might influence the number of subjects with an estimated glomerular filtration rate <60 ml/min/1.73 m². Therefore, a sensitivity analysis was performed, adopting increasingly stringent definitions of diabetic nephropathy. The results of this analysis support the conclusion that the 5-5 homozygous genotype is protective in women (see the online appendix).

The statistical power to detect a similar association in men as that seen in women ranged from 97 to 100% within the three diabetic nephropathy groups. Insufficient statistical power therefore does not explain the sex specific effect found in this study.

Limitations of this study are that ethnic origin is not defined by ethnic markers in these Caucasian populations and that sample sizes are relatively small. We performed a sensitivity analysis to exclude population stratification and a permutation analysis to rule out that our results are due to random fluctuation. These analyses support that population stratification or chance are unlikely to explain the sex specific effect found in this study (online appendix).

Another limitation is that the three diabetic nephropathy groups are compared with the same control group.

In conclusion, this study suggests a sex specific effect of the association between the *CNDP1* gene and diabetic nephropathy in three independent patient groups with diabetic nephropathy due to type 2 diabetes, with women being protected by the 5-5 homozygous genotype.

ACKNOWLEDGMENTS

This study was financially supported by the Leiden University Medical Center. Part of this study was supported by the EU-funded specifically targeted project, PREDICTIONS, to identify risk factors for developing diabetic nephropathy (FP6-018733). NECOSAD was supported by grants from the Dutch Kidney Foundation (E.018) and the Dutch National Health Insurance Board (OG97/005).

No potential conflicts of interest relevant to this article were reported.

We would like to express our gratitude to the Dutch Diabetes Research Foundation for supporting the Hindinef

study and the Health Research and Development Council of the Netherlands (ZonMw) for supporting the SUNSET study. We would also like to thank the members of the NECOSAD study group and the ZODIAC study group.

REFERENCES

1. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. *N Engl J Med* 1987;317:1390–1398
2. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1990;33:438–443
3. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. *N Engl J Med* 1989;320:1161–1165
4. Mooyaart AL, van Valkengoed IG, Shaw PK, Peters V, Baelde HJ, Rabelink TJ, Bruijn JA, Stronks K, de Heer E. Lower frequency of the 5/5 homozygous *CNDP1* genotype in South Asian Surinamese. *Diabetes Res Clin Pract* 2009;85:272–278
5. Maeda S. Genetics of diabetic nephropathy. *Ther Adv Cardiovasc Dis* 2008;2:363–371
6. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, Rychlik I, Cerna M, Romzova M, de Heer E, Baelde H, Bakker SJ, Zirie M, Rondeau E, Mathieson P, Saleem MA, Meyer J, Köppel H, Sauerhoefer S, Bartram CR, Nawroth P, Hammes HP, Yard BA, Zschocke J, van der Woude FJ. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene *CNDP1*. *Diabetes* 2005;54:2320–2327
7. Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, Xu J, McDonough C, Janssen B, Yard BA, van der Woude FJ, Bowden DW. A leucine repeat in the carnosinase gene *CNDP1* is associated with diabetic end-stage renal disease in European Americans. *Nephrol Dial Transplant* 2007;22:1131–1135
8. Wanic K, Placha G, Dunn J, Smiles A, Warram JH, Krolewski AS. Exclusion of polymorphisms in carnosinase genes (*CNDP1* and *CNDP2*) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. *Diabetes* 2008;57:2547–2551
9. Trégouët DA, Groop PH, McGinn S, Forsblom C, Hadjadj S, Marre M, Parving HH, Tarnow L, Telgmann R, Godefroy T, Nicaud V, Rousseau R, Parkkonen M, Hoverfält A, Gut I, Heath S, Matsuda F, Cox R, Kazeem G, Farrall M, Gauguier D, Brand-Hermann SM, Cambien F, Lathrop M, Vionnet N, EURAGEDIC Consortium. G/T substitution in intron 1 of the *UNC13B* gene is associated with increased risk of nephropathy in patients with type 1 diabetes. *Diabetes* 2008;57:2843–2850
10. McDonough CW, Hicks PJ, Lu L, Langefeld CD, Freedman BI, Bowden DW. The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans. *Hum Genet* 2009;126:265–275
11. Riedl E, Koeppl H, Brinkkoetter P, Sternik P, Steinbeisser H, Sauerhoefer S, Janssen B, van der Woude FJ, Yard BA. A CTG polymorphism in the *CNDP1* gene determines the secretion of serum carnosinase in Cos-7 transfected cells. *Diabetes* 2007;56:2410–2413
12. Hipkiss AR, Brownson C, Carrier MJ. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. *Mech Ageing Dev* 2001;122:1431–1445
13. Hobart LJ, Seibel I, Yeorgans GS, Seidler NW. Anti-crosslinking properties of carnosine: significance of histidine. *Life Sci* 2004;75:1379–1389
14. Mlynarski WM, Placha GP, Wolkow PP, Bochenski JP, Warram JH, Krolewski AS. Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in *RANTES* receptor gene (*CCR5*): a sex-specific effect. *Diabetes* 2005;54:3331–3335
15. Ihalmo P, Wessman M, Kaunisto MA, Kilpikari R, Parkkonen M, Forsblom C, Holthöfer H, Groop PH, FinnDiane Study Group. Association analysis of podocyte slit diaphragm genes as candidates for diabetic nephropathy. *Diabetologia* 2008;51:86–90
16. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). *Eur J Epidemiol* 2003;18:793–800
17. Levey AS, Gassman JJ, Hall PM, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. *J Am Soc Nephrol* 1991;1:1087–1094
18. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel

- A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol* 2009;20:1813–1821
19. Parving HH, Gall MA, Skøtt P, Jørgensen HE, Løkkegaard H, Jørgensen F, Nielsen B, Larsen S. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. *Kidney Int* 1992;41:758–762
20. Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. *J Am Soc Nephrol* 2009;20:1641–1649
21. Agyemang C, Bindraban N, Mairuhu G, Montfrans G, Koopmans R, Stronks K, SUNSET (Surinamese in The Netherlands: Study on Ethnicity and Health) Study Group. Prevalence, awareness, treatment, and control of hypertension among Black Surinamese, South Asian Surinamese and White Dutch in Amsterdam, The Netherlands: the SUNSET study. *J Hypertens* 2005;23:1971–1977
22. Bando K, Shimotsuji T, Toyoshima H, Hayashi C, Miyai K. Fluorometric assay of human serum carnosinase activity in normal children, adults and patients with myopathy. *Ann Clin Biochem* 1984;21:510–514
23. Peñafiel R, Ruzafa C, Monserrat F, Cremades A. Gender-related differences in carnosine, anserine and lysine content of murine skeletal muscle. *Amino Acids* 2004;26:53–58
24. Kimura N, Mizokami A, Oonuma T, Sasano H, Nagura H. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. *J Histochem Cytochem* 1993;41:671–678
25. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegiani S, Turco S, Velussi M, Ferrannini E, Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. *Diabetes Care* 2007;30:1241–1247